In Brief: P&G/Regeneron
Executive Summary
P&G/Regeneron: Agreement to develop therapeutics for muscle diseases and disorders is worth up to $28.8 mil. to Regeneron. The collaboration will draw on Procter & Gamble's skeletal muscle disease research and Regeneron's discovery of proteins "critical to the formation of a functional nerve-muscle unit," P&G says. P&G will purchase $10 mil. in Regeneron stock in the first half of 1997 and will make up to five $3.75 mil. annual payments to Regeneron. "Profits will be shared equally from any products jointly developed and marketed," P&G says...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth